-
National Health And Wellness Commission: No contribution can not be named papers! Not tied to performance or bonuses
Time of Update: 2021-03-24
Within 1 month after the publication of relevant papers and other scientific research results , To submit the original information to the institution After the completion of the research, medical scientific research personnel shall follow the corresponding biosafety and scientific research management regulations for the storage, sharing and destruction of human or animal samples, toxic substances, data or materials.
-
Health care committee replied to the NPC recommendations: high-value medical supplies adjusted out of the disposable equipment catalog
Time of Update: 2021-03-24
Reply to the suggestions made One-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
Reply to the suggestions made One-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
-
Interpretation | What should I do if there is a change in a listed Chinese medicine?
Time of Update: 2021-03-24
(6) The revised drug label sample draft with detailed revision instructions(7) Pharmaceutical research materialsCarry out research in accordance with the relevant technical guidelines for changes in the pharmacy of listed traditional Chinese medicines published by the National Drug Administration, and provide part or all of the pharmacy research and test data and necessary original registration applications according to the specific requirements of the relevant technical guidelines for various changes.
-
Merck and Day One collaborate to develop MEK inhibitor Pimasertib
Time of Update: 2021-03-24
Day One plans to further advance the Phase 1/2 study of the drug to evaluate the safety of Pimasertib in combination with DAY101 for the treatment of patients ≥12 years of age with relapsed, progressive or refractory solid tumors and abnormal MAPK pathway , Tolerability and preliminary efficacy.
-
Xianju Pharmaceutical: Received notification of acceptance of consistency evaluation of prednisone acetate tablets
Time of Update: 2021-03-24
They are commonly used, safe and effective drugs for the treatment of allergic and autoimmune inflammatory diseases.
The current product implementation standard is "Chinese Pharmacopoeia" 2020 edition two.
-
Last week 25 generic drugs passed the consistency evaluation and seven became injections
Time of Update: 2021-03-24
The Insight database shows that there are currently 7 companies submitting supplementary applications for consistency evaluation of Palonosetron Hydrochloride Injection, 4 companies have submitted applications for listing on the new registration classification, and 1 company is in the BE trial stage.
-
2021 Central No. 1 Document Released, Village-level Medical Services Ushered in a Big Change
Time of Update: 2021-03-24
The document proposes to comprehensively promote the construction of healthy villages, improve the standardization of village clinics and the level of health management, promote the transformation of rural doctors into practicing (assistant) doctors, and improve the level of grassroots health services by means of stationing and patrolling.
-
Global hot target new drug market pattern in 2020
Time of Update: 2021-03-23
Note: The data for 2020 does not include Carrelizumab (Hengrui), Tereprizumab (Junshi), Bavencio (Merck/Pfizer), Opdivo (Ono Pharmaceutical), 4 companies totaling approximately US$2 billionFrom the perspective of specific drug market realization, Keytruda continues to rise, with global sales increasing by 30%, reaching 14.
-
National Food and Drug Administration: These devices are recalled at the highest level
Time of Update: 2021-03-23
Medical Network News on March 5 Sales in China First level recall On March 3, the State Food and Drug Administration announced that Poco International Medical Trading (Shanghai) Co.
-
Fosun Pharma executives change!
Time of Update: 2021-03-23
Li Dongjiu, born in March 1965, is currently the Senior Vice President of Fosun Pharma.
(stock code: 01099), a company listed on the Hong Kong Stock Exchange Director, Vice President and General Counsel of Sinopharm Holdings Co.
-
"Angel" or "devil"?
Time of Update: 2021-03-23
Similar to "fentanyls", oxycodone has long been included in the narcotic control list, but its good effects can still occupy a place in the market.
In the analgesic family, such as dezocine, fentanyl and sufentanil, oxycodone all have good market prospects, although they are included in various control lists.
-
The National Food and Drug Administration approved the listing of Qingfei Paidu Granules, Huashibaidu Granules, and Xuanfeibaidu Granules
Time of Update: 2021-03-23
(CCTV reporter Yu Jingying) Medical Network, March 3 News On March 2, the National Medical Products Administration approved the Qingfei Paidu Granules of the Institute of Clinical Basic Medicine of Chinese Academy of Chinese Medical Sciences, the Huashibaidu Granules of Guangdong Yifang Pharmaceutical Co.
-
determine!
Time of Update: 2021-03-23
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
-
Health Commission: A large number of hospitals are restricted in surgery (list attached)
Time of Update: 2021-03-23
cn/news/yyzb/" target="_blank">purchase of consumables may drop After the list of restricted medical technologies is released, for the medical device industry, restricting the development of medical technologies means that related operations will be reduced, and the use of some equipment and consumables involved in operations will also be sharply reduced.
-
Xu Xiaofeng, general manager of Roche's general medicine division and specialty medicine division in China, resigns
Time of Update: 2021-03-23
After his departure from Roche Pharmaceuticals, the Specialty Drugs Division was temporarily managed by Qian Wei, Vice President of Roche Oncology First Division.
Later, he served as Vice President of General Medicines Division and Specialty Medicines Division and participated in the formulation of many core strategies of Roche Pharmaceuticals China.
-
From March 1st, the "crime of dereliction of duty in drug supervision" came
Time of Update: 2021-03-23
Medical Network News, March 2 On February 27, the official website of the Supreme People's Procuratorate issued the "Supplementary Provisions on the Implementation of the Criminal Law of the People's Republic of China on Determining Crimes (7)" (hereinafter referred to as the "Supplementary Provisions").
-
Successfully promote hair regrowth! Eli Lilly's JAK inhibitor reaches phase 3 clinical endpoint
Time of Update: 2021-03-23
Today, Eli Lilly and Company and Incyte jointly announced that the oral JAK inhibitor baricitinib has reached the primary endpoint in a phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (alopecia areata).
-
The review of AstraZeneca's anemia drug roxadustat was postponed again by the FDA
Time of Update: 2021-03-23
CompilationFan DongdongOn Monday, AstraZeneca and FibroGen said that the FDA will convene an AdComm advisory committee to review the effectiveness of roxadustat in the treatment of anemia in patients with chronic kidney disease who require dialysis and those who do not require dialysis.
-
National Medical Insurance Bureau: 49 cities across the country have piloted long-term care insurance
Time of Update: 2021-03-23
Wang Zhenhua, Section Chief of the Non-Basic Medical Insurance Section of the Medical Insurance Bureau of Wenjiang District, Chengdu: It has a prerequisite for long-term severe disability of more than 6 months due to illness, disability and other reasons, and there is no age limit.
-
Challenge Kelun's leading position!
Time of Update: 2021-03-23
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
